David Lebowitz
Stock Analyst at Citigroup
(2.44)
# 2,327
Out of 4,767 analysts
108
Total ratings
46.75%
Success rate
-1.29%
Average return
Main Sectors:
Stocks Rated by David Lebowitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PLRX Pliant Therapeutics | Maintains: Neutral | $4 → $1.5 | $1.54 | -2.60% | 6 | Mar 4, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Neutral | $12 → $14 | $9.14 | +53.17% | 7 | Feb 28, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $45 → $49 | $32.97 | +48.62% | 3 | Feb 21, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $67 → $64 | $32.96 | +94.17% | 12 | Feb 20, 2025 | |
| EXEL Exelixis | Maintains: Buy | $38 → $45 | $36.65 | +22.78% | 2 | Feb 12, 2025 | |
| PTCT PTC Therapeutics | Maintains: Sell | $32 → $45 | $54.50 | -17.43% | 4 | Feb 12, 2025 | |
| INCY Incyte | Maintains: Buy | $97 → $88 | $67.86 | +29.68% | 5 | Feb 11, 2025 | |
| VKTX Viking Therapeutics | Initiates: Neutral | $38 | $30.89 | +23.02% | 1 | Feb 7, 2025 | |
| CYTK Cytokinetics | Initiates: Buy | $86 | $44.36 | +93.87% | 1 | Feb 7, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Buy | $65 → $68 | $44.28 | +53.57% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $20.42 | +242.80% | 1 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $15 | $7.14 | +110.08% | 3 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $178 → $207 | $152.98 | +35.31% | 12 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $65 → $76 | $89.58 | -15.16% | 5 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $39 → $37 | $22.90 | +61.57% | 9 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $382 | $348.35 | +9.66% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $103 → $96 | $69.44 | +38.25% | 3 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $12 | $1.60 | +650.00% | 2 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $170 → $164 | $241.76 | -32.16% | 7 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 → $39 | $14.62 | +166.76% | 6 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $21 | $12.95 | +62.16% | 11 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $435 → $405 | $6.75 | +5,900.00% | 1 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $13 → $14 | $1.49 | +839.60% | 2 | Oct 12, 2021 |
Pliant Therapeutics
Mar 4, 2025
Maintains: Neutral
Price Target: $4 → $1.5
Current: $1.54
Upside: -2.60%
Intellia Therapeutics
Feb 28, 2025
Maintains: Neutral
Price Target: $12 → $14
Current: $9.14
Upside: +53.17%
BridgeBio Pharma
Feb 21, 2025
Maintains: Buy
Price Target: $45 → $49
Current: $32.97
Upside: +48.62%
Ionis Pharmaceuticals
Feb 20, 2025
Maintains: Buy
Price Target: $67 → $64
Current: $32.96
Upside: +94.17%
Exelixis
Feb 12, 2025
Maintains: Buy
Price Target: $38 → $45
Current: $36.65
Upside: +22.78%
PTC Therapeutics
Feb 12, 2025
Maintains: Sell
Price Target: $32 → $45
Current: $54.50
Upside: -17.43%
Incyte
Feb 11, 2025
Maintains: Buy
Price Target: $97 → $88
Current: $67.86
Upside: +29.68%
Viking Therapeutics
Feb 7, 2025
Initiates: Neutral
Price Target: $38
Current: $30.89
Upside: +23.02%
Cytokinetics
Feb 7, 2025
Initiates: Buy
Price Target: $86
Current: $44.36
Upside: +93.87%
Mirum Pharmaceuticals
Nov 13, 2024
Maintains: Buy
Price Target: $65 → $68
Current: $44.28
Upside: +53.57%
Oct 7, 2024
Initiates: Buy
Price Target: $70
Current: $20.42
Upside: +242.80%
Sep 24, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $7.14
Upside: +110.08%
Sep 17, 2024
Maintains: Buy
Price Target: $178 → $207
Current: $152.98
Upside: +35.31%
May 3, 2024
Maintains: Sell
Price Target: $65 → $76
Current: $89.58
Upside: -15.16%
May 2, 2024
Maintains: Buy
Price Target: $39 → $37
Current: $22.90
Upside: +61.57%
Mar 6, 2024
Initiates: Buy
Price Target: $382
Current: $348.35
Upside: +9.66%
Jun 30, 2023
Maintains: Neutral
Price Target: $103 → $96
Current: $69.44
Upside: +38.25%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $18 → $12
Current: $1.60
Upside: +650.00%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $170 → $164
Current: $241.76
Upside: -32.16%
Jun 7, 2022
Maintains: Overweight
Price Target: $36 → $39
Current: $14.62
Upside: +166.76%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $20 → $21
Current: $12.95
Upside: +62.16%
Oct 12, 2021
Maintains: Overweight
Price Target: $435 → $405
Current: $6.75
Upside: +5,900.00%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $13 → $14
Current: $1.49
Upside: +839.60%